PARP1 and ovarian carcinoma: It has already been shown that PARP-1 inhibition can potentiate the effects of chemotherapy in triple-negative breast cancer40, as well as improve progression-free survival for patients with ovarian cancer sensitive to platinum-based agents41,42.